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Suppression of aromatase in human breast cells by a
cyclooxygenase-2 inhibitor and its analog involves multiple
mechanisms independent of cyclooxygenase-2 inhibition
Bin Su, Edgar S. Dı´az-Cruz, Serena Landini, Robert W. Brueggemeier
Introduction
Breast cancer is the second leading cause of cancer death in
women in the United States, and an estimated 212,930women
in the United States will be diagnosed with breast cancer
in 2006 [1]. Approximately two-thirds of breast cancers are
termed hormone-dependent breast cancers, contain estrogen
receptors (ER), and require estrogen for tumor growth. Treat-
ment of ER-positive breast cancer cases includes hormonal
therapies such as aromatase inhibitors (AIs) or antiestro-
gens/selective estrogen modulators (SERMs) [2].
The most commonly used SERM is tamoxifen, which
inhibits the growth of breast tumors by competitive antag-
onism of estrogen at the ER ligand binding site. However,
development of drug resistance and increased uterine and
endometrial cancer reduce its clinical application [3–5].
In contrast, AIs markedly suppress plasma estrogen lev-
els by inhibiting aromatase, the cytochrome P450 enzyme
responsible for the synthesis of estrogens from androgenic
precursors. However, these compounds inhibit aromatase
activity in a global fashion and thus could adversely
impact sites where estrogen is required for normal func-
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tion. The risk of important long-term reduction in bone
density, including osteoporosis, may increase with the use
of aromatase inhibitors [6–8]. Short-term use of letrozole
has been associated with an increase in bone-resorption
markers in plasma and urine, and adjuvant therapy with
anastrozole appears to be associated with a higher inci-
dence of fractures than adjuvant therapy with tamoxifen
[9–11].
A new approach to reduce the risk of side effects is to
develop agents that regulate aromatase expression in a tissue-
speciﬁc manner. In postmenopausal women, estrogens are
produced locally in the breast by aromatase. Higher lev-
els of estrogens in breast cancer cells and breast adipose
tissue stimulate tumor growth by binding to estrogen recep-
tors in both an autocrine and a paracrine manner [12–14].
In humans, cytochrome P450 aromatase is encoded by the
CYP19 gene, which contains nine coding exons (exons II–X).
The expression of this gene is regulated in a tissue-speciﬁc
manner by the alternative use of eight promoters, each one
of them being associated with a speciﬁc 5′ untranslated
exon I [15]. Furthermore, due to the unique organization of
tissue-speciﬁc promoters, various promoters employ differ-
ent signaling pathways and different transcription factors
[16–20].
One of the major stimulators of aromatase expression in
cancer breast is prostaglandin E2 (PGE2) derived from tumor-
ous epithelium and/or inﬁltrating macrophages. PGE2 acts via
EP1 and EP2 receptor subtypes to stimulate both the protein
kinase A and protein kinase C pathways to increase aro-
matase expression through promoter II and promoter I.3 in
breast stromal cells [21–24]. Moreover, expression of the CYP19
gene is correlated with COX-1 and COX-2 expression in human
breast cancer [25]. This biochemical mechanism may explain
epidemiological observations of the beneﬁcial effect of non-
steroidal anti-inﬂammatory drugs (NSAIDs) on breast cancer.
Recently, the COX-2 selective inhibitor, celecoxib, has shown
strong chemopreventive activity againstmammary carcinoma
in rats [26].
COX-2 inhibitors can suppress aromatase activity in breast
cancer cells by suppressing aromatase transcription [27].
However, the suppression varied signiﬁcantly among COX-
2 inhibitors. This observation suggests differences in the
mechanisms by which these COX inhibitors modulate aro-
matase expression in breast cancer cells. Among all the
tested COX-2 inhibitors, NS-398 showed the highest potency
in suppressing aromatase transcription and activity com-
pared to other COX-2 inhibitors studied. On the other hand,
NS-398 is a weak inhibitor of COX-2. Thus, NS-398 may
target aromatase gene regulation through other pathways
independent of direct COX-2 inhibition. To investigate poten-
tial mechanisms for NS-398 suppression of aromatase, we
synthesized N-Methyl NS-398 (Me-NS-398) (Fig. 1), which
does not have COX-2 inhibitory activity but has very sim-
ilar chemical structure to NS-398 [28]. N-Methyl NS-398
suppresses aromatase expression and activity in SK-BR-3
breast cancer cells at similar extent with NS-398. In the
present study, we investigated the effects of these two
agents on the regulation of aromatase expression in other
human breast cancer cells and in breast stromal cells from
patients.
Fig. 1 – Structure of NS-398 and N-Methyl NS-398 and their
COX-2 inhibition results in MDA-MB-231 cell line [28].
Materials and methods
Reagents
Radiolabeled [1-3H]-androst-4-ene-3,17-dione was obtained
from NEN Life Science Products (Boston, MA). NS-398 and
Ru486 was purchased from Cayman Chemical (Ann Arbor,
MI). Me-NS-398 was synthesized in our laboratory [28]. For
in vitro experiments, these agents at various concentrations
were dissolved inDMSO. Trypsin, TRIzol, and all enzymeswere
obtained from Invitrogen (Carlsbad, CA). Radioactive samples
were counted on a LS6800 liquid scintillation counter (Beck-
man, Palo Alto, CA). Scintillation solution 3a70B was obtained
from Research Prospect International Corp. (Mount Prospect,
IL). Tetradecanoyl phorbol acetate (TPA), dexamethasone
(DEX), forskolin (FSK), NADP+ and glucose-6-phosphate dehy-
drogenasewere purchased from Sigma (St. Louis, MO). Human
tissues (breast cancer, placenta) were obtained through
OSUCCC Tissue Procurement under IRB-approved protocols
OSU #2002H0104 and OSU #2002H0105.
Cell culture
MCF-7 cells and MDA-MB-231 cells were obtained from ATCC
(Rockville, MD). Cell cultures were maintained in phenol red-
free custom media (MEM, Earle’s salts, 1.5× amino acids, 2×
nonessential amino acids, l-glutamine, 1.5× vitamins, Gibco
BRL) supplemented with 10% fetal bovine serum (FBS), 2mM
l-glutamine and 20mg/L gentamycin. Adipose stromal cells
were obtained as described [29] and maintained in DMEM/F12
media with 10% FBS, 2mM l-glutamine and 20mg/L gen-
tamycin. Fetal bovine serum was heat inactivated for 30min
in a 56 ◦C water bath before use. Cell cultures were grown at
37 ◦C, in a humidiﬁed atmosphere of 5% CO2 in a Hereaus CO2
incubator. For all experiments, cells were plated in either T-25
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ﬂasks or 100mM plates and grown to subconﬂuency. Before
treatment, the media was changed to deﬁned media con-
sisting of DMEM/F12 media (Sigma) with 1.0mg/mL human
albumin (OSU Hospital Pharmacy), 5.0mg/L human transferin
and 5.0mg/L bovine insulin.
Tritiated water-release assay in cells
Measurement of aromatase enzyme activity in cells was based
on the tritium water release assay [24]. Cells in T-25 ﬂasks or
100mM plates were treated with DMSO (control), NS-398 and
N-methyl NS-398 for 24h. In the combination studies, cells
were pre-treated with FSK/TPA or DEX for 24h, then in combi-
nation with the indicated compounds for 24h. After 24h, cells
were then incubated for 6hwith freshmedia containing drugs
and 2Ci [1-3H]-androst-4-ene-3,17-dione (100nM). Subse-
quently, the reactionmixture was removed, and proteins were
precipitated using 10% trichloroacetic acid at 42 ◦C for 20min.
After a brief centrifugation, the media was extracted three
times with an equal amount of chloroform to extract unused
substrate, and the aqueous layer subsequently treated with
1% dextran-treated charcoal. After centrifugation, a 250L
aliquot containing the product was counted in 5mL of liquid
scintillation mixture. Each sample was run in triplicate and
results were corrected for blanks and for the cell contents of
culture ﬂasks. Results were expressed as picomoles of 3H2O
formed per hour incubation time permillion cells (pmol/h/106
cells). To determine the amount of live cells in each ﬂask, the
cells were trypsinized and analyzed using the diphenylamine
DNA assay adapted to a 96-well plate [24,30].
Preparation of human placental microsomes
Human placentas were processed immediately after delivery
from The Ohio State University Hospitals at 4 ◦C. The placenta
was washed with normal saline, and connective and vascu-
lar tissue was removed. Microsomes were prepared from the
remaining tissue using the method described by Kellis and
Vickery [31]. Microsomal suspensions were stored at −80 ◦C
until required.
Tritiated water-release assay with human
placental microsomes
Inhibition of human placental aromatase was determined
by monitoring the amount of tritium water released as
the enzyme converts [1-3H] androst-4-ene-3,17-dione to
estrone [32]. Aromatase activity assays were carried in
0.1M potassium phosphate buffer (pH 7.0) with 5% propy-
lene glycol. All samples contained a NADPH regenerating
system consisting of 2.85mM glucose-6-phosphate, 1.8mM
NADP+ and 1.5 units of glucose-6-phosphate dehydroge-
nase. Samples contained 100nM androst-4-ene-3, 17-dione
(400,000–450,000dpm). Reactionswere initiatedwith the addi-
tion of 50gmicrosomal protein. The total incubation volume
was 2.0mL. Incubations were allowed to proceed for 15min in
a shaking water bath at 37 ◦C. Reactions were quenched by the
addition of 2.0mL of chloroform. Samples were then vortexed
and centrifuged for 5min and the aqueous layer was removed.
The aqueous layer was subsequently extracted twice in the
same manner with 2.0mL chloroform. A 0.5mL aliquot of the
ﬁnal aqueous layer was combined with 5mL 3a70B scintilla-
tion cocktail and the amount of radioactivity was determined.
Each samplewas run in triplicate and background valueswere
determined with microsomal protein inactivated by boiling.
RNA extraction
Total RNA was isolated using the TRIzol reagent according
to the manufacturer’s protocol. Total RNA pellets were dis-
solved in DNase, RNase-free water and quantitated using a
spectrophotometer. The quality of RNA samples was deter-
mined by electrophoresis through agarose gels and staining
with ethidium bromide; the 18S and 28S rRNA bands were
visualized under ultraviolet light.
cDNA synthesis
Isolated total RNA (2g) was treated with DNase I Ampli-
ﬁcation grade, according to the recommended protocol to
eliminate any DNA before reverse transcription. Treated total
RNA was denatured at 65 ◦C for 5min in the presence of
2.5ng/L random hexamers and 0.5mM dNTP mix. The
sampleswere snap-cooled on ice and centrifugedbrieﬂy. Com-
plementary DNA (cDNA) was synthesized using Superscript
II reverse transcriptase according to the recommended proto-
col. Brieﬂy, the reactionswere conducted in the presence of 1X
First-Strand Buffer and 20mMDTT at 42 ◦C for 50min and con-
sequently inactivated at 70 ◦C for 15min. The cDNA generated
was used as a template in real-time PCR reactions.
Real-time PCR
Real-time PCR was performed using the OpticonTM 2 system
from MJ Research (Waltham, MA). For the CYP19 total gene
the PCR reaction mixture consisted of Taqman® Universal
PCR Master Mix (Applied Biosystems), 600nM of CYP19 primer
(sense: 5′-TGT CTC TTT GTT CTT CAT GCT ATT TCT C-3′; anti-
sense: 5′-TCA CCA ATA ACA GTC TGG ATT TCC-3′); 250nM
Taqman probe (6FAM 5′-TGC AAA GCA CCC TAA TGT TGA
AGA GGC AAT-3′TAMRA)(Invitrogen), and 2.0L of each cDNA
sample in a ﬁnal volume of 20L. For the 18S house keep-
ing total gene the PCR reaction mixture consisted of Taqman®
Universal PCR Master Mix (Applied Biosystems), 500nM of 18S
primer (sense: 5′-CAG TTC ATA CAG CGG AAC ACT G-3′; anti-
sense: 5′-TTT GCT GGA GAA CAG GGC TG-3′); 50nM Taqman
probe (6FAM 5′-TGC TGG CAC CAG ACT TGC CCT C-3′TAMRA)
(Invitrogen), and 2.0L of each cDNA sample in a ﬁnal vol-
ume of 20L. The Taqman probes for aromatase and 18S were
designed to anneal to a speciﬁc sequence of the aromatase
and 18S gene correspondingly between the forward and the
reverse primers. Cycling conditions were 50 ◦C for 2min and
95 ◦C for 10min, followed by 50 cycles at 95 ◦C for 15 s and 60 ◦C
for 1min.
Cell proliferation assay
MCF-7 cells were harvested, counted, and plated at a con-
centration of 1× 104 cells/well in 400l total volume/well in
24-well plates. After 24h, the culture medium was removed
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and changed to DMEM/F12 media supplemented with 5%
charcoal stripped FBS. After 24h, culture wells (n=6) were
treated with the compounds combined with or without
Testosterone (100nM) (400l volume) every 2 days for a
total of 6 days. Twenty-four hours after the last treatment,
3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt and phenazine
methosulfate were prepared in PBS at a ﬁnal assay concentra-
tions of 333g/mL and 25M, respectively. These solutions
were combined and 50l of this mixture were added to each
well. After 1h of incubation at 37 ◦C, absorbance at 490nm
was measured using a SPECTRAmax plate reader.
Statistical analysis
Statistical and graphical information was determined using
GraphPad Prism software (GraphPad Software Incorporated)
and Microsoft Excel (Microsoft Corporation). Determination of
IC50 values were performed using nonlinear regression anal-
ysis. Statistically signiﬁcant differences were calculated with
the two-tailed unpaired Student’s t-test and P values reported
at 95% conﬁdence intervals.
Results
Decrease of aromatase enzymatic activity in
MCF-7 and MDA-MB-231 breast cancer cells
PGE2 produced in breast cancer tissue regulates aromatase
expression through PKA/PKC driven pathway in an autocrine
and paracrine manner in breast cells [23,24]. COX inhibitors
were able to suppress aromatase in breast cancer cells at the
transcriptional level. However, COX-2 inhibitors which have
similar IC50 values for COX-2 inhibition differ signiﬁcantly in
their ability to suppress aromatase activity.NS-398 showed the
highest potency in suppressing aromatase activity compared
to other agents tested such as celecoxib [27]. We hypothesize
that NS-398 may target regulation of aromatase gene tran-
scriptionmore effectively through other pathways than direct
COX-2 inhibition. To test this hypothesis, we synthesized
NS-398 derivative Me-NS-398(N-methyl-N-(2-cyclohexyloxy-
4-nitrophenyl)methanesulfonamide), which does not inhibit
PGE2 production (Fig. 1) [28].
The effects of NS-398 andMe-NS-398 on aromatase activity
are determined inMCF-7 andMDA-MB-231 breast cancer cells.
At 25M, both compounds signiﬁcantly decreased aromatase
activity in the two cell lines (Fig. 2). At 5M, both compounds
only decreased aromatase activity in MCF-7 cells. Thus, Me-
NS-398 and NS-398 exhibit similar effects on the suppression
of aromatase activity in both breast cancer cell lines.
Aromatase activity assay in human placental
microsomes
The compounds were tested for potential direct aromatase
inhibition in the microsomal aromatase assay to determine
if the decrease of aromatase activity is due to direct enzyme
inhibition. These investigations ﬁnd that NS-398 and Me-
NS-398 produce only weak inhibition of aromatase with IC50
Fig. 2 – Suppression of aromatase activity in MCF-7 and
MDA-MB-231 breast cancer cells. Cells were treated with
NS-398 and MNS-398 at indicated concentrations. The
results were normalized against a control treatment with
vehicle. Each data bar represents the mean results of three
independent determinations. (A) MCF-7 cells, the value of
100% is equal to 0.0002pmol/h/106 cells. (B) MDA-MB-231
cells, the value of 100% is equal to 0.00007pmol/h/106 cells.
*P<0.05 vs. control by unpaired t-test.
values of 26.5 and19.3M, respectively (Fig. 3). The results sug-
gest that the suppression of aromatase activity by NS-398 and
Me-NS-398 in MCF-7 and MDA-MB-231 cells by direct enzyme
inhibition may only be observed at high concentrations.
Fig. 3 – Aromatase inhibition of microsomal activities of
compounds NS-398 () and Me-NS-398 (). Error bars
represent standard error (n=3), and the data were
statistically analyzed by a nonlinear regression analysis
method.
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Fig. 4 – Real-time RT-PCR analysis of CYP19 mRNA
expression in MCF-7 (A) and MDA-MB-231 cells (B). Cells
were treated for 24h with the test agents at different
concentrations, and total RNA was isolated. Results are
expressed as means of CYP19 (normalized to 18S
rRNA)±S.E.M. *P<0.05 vs. control by unpaired t test (n=9).
CYP19 mRNA expression by real-time PCR in
MCF-7 and MDA-MB-231 cells
Analysis of total CYP19 mRNA transcripts was performed
using real-time PCR in order to assess the extent of suppres-
sion in aromatase activity by NS-398 and Me-NS-398 through
down-regulation of aromatase expression at transcriptional
level. Cells were treated with NS-398 and Me-NS-398 for 24h
at 5 and 25M. Total RNA was extracted after 24h, and CYP19
transcript levels are compared to control (vehicle) treatment.
Both compounds signiﬁcantly decreased CYP19 gene expres-
sion in the two cell lines relative to the control at 25M (Fig. 4).
No effect on the expression level of the housekeeping gene 18S
rRNA was observed with any of the compounds. At 5M, both
compounds did not decrease CYP19 gene expression, but they
suppressed aromatase activity in MCF-7 cells (Fig. 3A). This
suppression of enzyme activity is not likely to occur through
direct enzyme inhibition, because the drug concentration in
this experiment is much lower than the IC50 value from the
microsomal aromatase inhibition study. This suggests that a
nongenomic mechanism may also be involved in suppression
of cellular aromatase activity. In all the experiments, Me-NS-
398 decrease aromatase activity and expression to a similar
extent; thus, NS-398 and Me-NS-398 apparently target other
pathway(s) to suppress aromatase.
Fig. 5 – Effect of NS-398 and Me-NS-398 on induced
aromatase in breast cancer cells. Cells were pre-treated
with FSK(25M)/TPA (10nM) or DEX(200nM) for 24h, then
with the indicated compounds (2M), Ru486(200nM) and
FSK/TPA or DEX for 24h. Aromatase activity was
subsequently determined during a 6h assay as described.
*p<0.05 vs. FSK/TPA or DEX treatment for suppression of
induced aromatase activity; **p<0.05 vs DMSO treatment
for stimulation of aromatase activity by unpaired t test
(n=3). (A) MCF-7 cells, the value of 100% is equal to
0.0002pmol/106 cells/h. (B) MDA-MB-231 cells, the value of
100% is equal to 0.00007pmol/106 cells/h. Similar results
were obtained in at least two independent experiments.
NS-398 and Me-NS-398 suppress aromatase
stimulated by FSK/TPA in breast cancer and stromal cells
FSK/TPA can stimulate aromatase activity by activating PKA
and PKC pathways, which are the major pathways to stimu-
late aromatase expression in breast cancer. DEX stimulates
aromatase expression by binding to glucocorticoid recep-
tor, which is the main pathway for aromatase expression
in normal breast, skin and bone tissue [18,22,23]. The effect
of NS-398 and Me-NS-398 on the aromatase activity stimu-
lated by FSK (25M)/TPA (10nM) or DEX (200nM) in MCF-7
and MDA-MB-231 cells was examined. NS-398 and Me-NS-
398 at 2M did not suppress aromatase activity stimulated by
DEX, whereas DEX stimulation could be suppressed by RU486
(200nM), a glucocorticoid receptor antagonist, inMDA-MB-231
cells (Fig. 5B). On the other hand, the two agents suppress aro-
matase activity stimulated by FSK/TPA in MCF-7 cells at 2M
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Fig. 6 – Effect of NS-398 and Me-NS-398 on induced CYP19
gene expression in MCF-7 breast cancer cells. Cells were
pre-treated with FSK(25M)/TPA (10nM) for 24h, then with
the indicated compounds (2M) and FSK/TPA for 24h. Total
RNA was isolated. Results are expressed as means of CYP19
(normalized to 18S rRNA)±S.E.M., *p<0.05 vs. FSK/TPA
treatment for suppression of induced aromatase
transcription; **p<0.05 vs. DMSO treatment for stimulation
of aromatase transcription by unpaired t-test (n=9). Similar
results were obtained in at least two independent
experiments.
(Fig. 5A). Furthermore, we ﬁnd that this suppression of aro-
matase activity occurs at the transcriptional level (Fig. 6). This
suggests that these agents affect PKA/PKC-driven transcrip-
tion of aromatase. FSK/TPA does not stimulate aromatase in
MDA-MB-231cells, and DEX does not stimulate aromatase in
MCF-7 cells (Fig. 5B lane 5; Fig. 5A lane 5). For MCF-7 cells,
the aromatase transcription occurs primarily via promoter I.3
Fig. 7 – Effect of NS-398 and Me-NS-398 on induced
aromatase in breast stromal cells. Cells were pre-treated
with FSK(10M)/TPA (10nM) or DEX(200nM) for 24h, then
with the indicated compounds (2M), Ru486(200nM) and
FSK/TPA or DEX for 24h. Aromatase activity was
subsequently determined during a 6h assay as described.
*p<0.05 vs. FSK/TPA or DEX treatment for suppression of
induced aromatase activity; **p<0.05 vs. DMSO treatment
for stimulation of aromatase activity by unpaired t-test
(n=3). The value of 100% is equal to 0.00012pmol/106
cells/h. Similar results were obtained in at least two
independent experiments.
Fig. 8 – Effect of NS-398 and Me-NS-398 on induced CYP19
gene expression in breast stromal cells. Cells were
pre-treated with FSK (10M)/TPA (10nM) for 24h, then with
the indicated compounds (2M) and FSK/TPA for 24h. Total
RNA was isolated. Results are expressed as means of CYP19
(normalized to 18S rRNA)±S.E.M. *p<0.05 vs. FSK/TPA
treatment for suppression of induced aromatase
transcription; **p<0.05 vs. DMSO treatment for stimulation
of aromatase transcription by unpaired t-test (n=9). Similar
results were obtained in at least two independent
experiments.
and II. Promoter I.4 is not detected in this cell line [17], which
may explain why DEX cannot stimulate promoter I.4 driven
aromatase transcription.
In addition, NS-398 and Me-NS-398 at 2M decreased the
aromatase activity stimulated by FSK (10M)/TPA (10nM) in
breast stromal cells, and this suppression occurred at the
transcriptional level (Figs. 7 and 8). NS-398 and Me-NS-398 at
2M do not suppress aromatase activity stimulated by DEX
(200nM).
NS-398 and Me-NS-398 signiﬁcantly suppressed
testosterone induced MCF-7 cell proliferation
Treatment of MCF-7 cells with NS-398 or Me-NS-398 did not
signiﬁcantly affect normal MCF-7cell proliferation at 2M
(Fig. 9). Since the aromatase enzyme is present in MCF-7
cells, testosterone can be converted to estradiol and stimulate
MCF-7 cell growth [33,34]. In this present study, testosterone
(100nM) signiﬁcantly increase MCF-7 cell proliferation. Both
NS-398 and Me-NS-398 suppressed testosterone-induced cell
proliferation inMCF-7 cells, presumable by suppression of aro-
matase expression and subsequently lack of conversion of
testosterone to estradiol.
Discussion
Increased aromatase expression in breast cancer tissue is
associated with a switch in promoter usage from the normal
adipose-speciﬁc promoter I.4 to the PGE2-responsive pro-
moter II and promoter I.3. While promoter I.4 requires the
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Fig. 9 – Antiproliferation effect of NS-398 and Me-NS-398 in
MCF-7 cells. MCF-7 cells were seeded into 24 wells plates at
∼1×104/well and exposed to testosterone (T, 100nM) or the
test agent (NS-398 and Me-NS-398 at 2M) plus
testosterone (100nM) in DMEM/F12 media supplemented
5% charcoal stripped fetal bovine serum. Cell viability was
measured as described in the experimental section. The
results were normalized against a control treatment with
vehicle (DMSO). *p<0.05 vs. testosterone treatment for
suppression of induced proliferation; **p<0.05 vs. control
for stimulation of proliferation by unpaired t-test (n=6).
Similar results were obtained in at least two independent
experiments.
synergistic actions of glucocorticoids and class I cytokines
[19], promoters I.3 and II are both transactivated via PKA
and PKC dependent signaling pathways [19,35]. This switch
in the regulatory mechanism of aromatase expression from
normal breast tissue to cancerous tissue has been exten-
sively investigated [36]. Our hypothesis is that higher levels
of COX-2 expression result in higher levels of PGE2, which in
turn results in increased CYP19 expression. Potentially, COX-
2 inhibitors could inhibit aromatase expression selectively in
cancer breast tissue; therefore, COX-2 inhibitors may be clas-
siﬁed as the ﬁrst generation of selective aromatase expression
regulators for ER positive breast cancer.
In our previous study [27], the COX-2 selective inhibitor NS-
398 suppressed aromatase transcription and activity in breast
cancer cells signiﬁcantly better than other COX-2 inhibitors,
even though NS-398 has weaker COX-2 inhibitory activity.
These results suggested that other mechanisms may also
be involved in regulation of aromatase expression by COX
inhibitors. VariousNSAIDs can inﬂuence the expression of cer-
tain transcription factors and other pathway mediators that
could result in the suppression of aromatase.
To elucidate the phenomenon, Me-NS-398, which is devoid
of COX-2 inhibitory activity, was synthesized and studied
previously in SK-BR-3 breast cancer cells [28]. The biologi-
cal activities of NS-398 and Me-NS-398 on aromatase were
investigated here in MCF-7 and MDA-MB-231 breast cancer
cells, normal breast stromal cells and also in microsomal
aromatase assays. The results showed that Me-NS-398 and
NS-398 suppressed aromatase activity and expression in these
breast cancer cells. Microsomal aromatase inhibition stud-
ies further demonstrated that the compounds only inhibit
aromatase enzyme at high concentrations. NS-398 and Me-
NS-398 suppressed CYP19 gene expression in both MCF-7 and
MDA-MB-231 cell lines as measured by real time PCR. These
results suggest that the compounds suppress aromatase activ-
ity in breast cancer cells via multiple mechanisms.
To further investigate the possible mechanism(s) in sup-
pression of aromatase expression, the compoundswere tested
for their ability to suppress aromatase in breast cancer and
stromal cells stimulated by FSK/TPA or DEX, which induce
aromatase expression via different pathways and promoters.
FSK/TPA stimulates aromatase via PKA and PKC pathways,
and DEX induces aromatase via glucocorticoid receptor medi-
ated transcription. The results demonstrated that NS-398
and Me-NS-398 suppressed aromatase activity by decreas-
ing PKA/PKC driven transcription (FSK/TPA stimulated) and
did not interfere with normal breast aromatase expression
mediated through glucocorticoid receptor (DEX stimulated)
in both breast epithelial and stromal cells. Additionally, the
compounds inhibited testosterone stimulated MCF-7 cell pro-
liferation, which also suggests that the compounds are able to
decrease aromatase activity.
In summary, thoughN-methylNS-398doesnot showCOX-2
inhibitory activity, it decreases aromatase activity and expres-
sion in breast cancer cells to a similar extent as NS-398. This
suggests NS-398 decreases aromatase expression in breast
cells by other mechanism(s) other than COX-2 inhibition.
These two compounds selectively affected aromatase stim-
ulated from PKA/PKC pathway, which are the major pathways
involved in aromatase expression in breast cancer. Con-
sequently, our current research focuses on discerning the
speciﬁc molecular target of the compounds and identifying a
novel molecular basis for the development of selective aro-
matase expression regulators. In addition, investigations of
structural requirements for aromatase suppression of NS-398
and analogs are on-going.
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